Connect your AI

Replimune Group REPL Estimated Fair Value

Estimated Fair Value at other companies

Summit TherapeuticsSMMT

——

IncyteINCY

——

GRAIL, Inc.GRAL

——

Other financials

Income statement

Operating income-$71.9M-8.9%

Net income-$70.9M-6.9%

EPS (diluted)-$0.77+2.5%

Balance sheet

Cash & equivalents$124.7M-28.3%

Total debt$79.2M+0.5%

Total equity$210.5M-56.4%

Total assets$333.6M-44.7%

Cash flow

Operating cash flow-$66.0M-30.1%

CapEx$135.0K-92.5%

Free cash flow-$66.1M-25.9%

Valuation

Market cap$930.59M+28.6%

Enterprise value$885.15M+28.3%

Returns & leverage

Return on equity-90.9%+362pp

Debt / equity0.4×+0.2×

Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's estimated fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Replimune Group's estimated fair value?: Replimune Group (REPL) reported estimated fair value of $146.19M in Q4 2025.